Skip to main content
Equibles

Squarepoint Ops LLC

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1642575 NEW YORK, NY
Back to REGN Full portfolio

Position in REGN

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$125,796,608
+$123,723,366 QoQ
Shares Held
162,814
+5961.6% QoQ
Ownership
0.155%
of shares outstanding
% of Portfolio
0.34%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
24 quarters on record
Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Common Shares in REGN Over Time

Shares Held

Position Value (USD)

Derivatives in REGN

reported options exposure · as of Mar 31, 2026
CallValue
$8,421,776
CallShares
10,900
PutValue
$7,108,288
PutShares
9,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Squarepoint Ops LLC holds $1,094,556,775 across 232 Biotechnology names. REGN ranks #2 (11.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 426,723 $141,189,839
2 REGN
Regeneron Pharmaceuticals, Inc.
This page 		162,814 $125,796,608
3 RPRX
Royalty Pharma plc
 1,349,516 $64,736,282
4 IONS
Ionis Pharmaceuticals Inc
 695,276 $52,208,274
5 BBIO
BridgeBio Pharma, Inc.
 556,324 $41,312,620
6 MDGL
Madrigal Pharmaceuticals, Inc.
 52,884 $27,683,187
7 ARQT
Arcutis Biotherapeutics, Inc.
 1,103,490 $25,998,224
8 FOLD
AMICUS THERAPEUTICS, INC.
 1,705,829 $24,666,287

All Filings in REGN

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $125,796,608 162,814
2026-03-31 $8,421,776 10,900
2026-03-31 $7,108,288 9,200
2025-12-31 $5,634,651 7,300
2025-12-31 $2,073,242 2,686
2025-12-31 $21,612,360 28,000
2025-09-30 $37,262,195 66,271
2025-09-30 $14,619,020 26,000
2025-09-30 $3,654,755 6,500
2025-06-30 $156,287,775 297,691
2025-06-30 $25,042,500 47,700
2025-06-30 $7,140,000 13,600
2025-03-31 $12,494,331 19,700
2025-03-31 $17,060,787 26,900
2025-03-31 $180,123,222 284,003
2024-12-31 $181,344,259 254,579
2024-12-31 $37,753,490 53,000
2024-12-31 $29,205,530 41,000
2024-09-30 $16,399,344 15,600
2024-09-30 $43,205,964 41,100
2024-09-30 $16,399,344 15,600
2024-06-30 $3,020,660 2,874
2024-06-30 $14,399,111 13,700
2024-06-30 $16,185,862 15,400
2024-03-31 $17,517,318 18,200
2024-03-31 $5,073,284 5,271
2024-03-31 $18,672,306 19,400
2023-12-31 $37,909,631 43,163
2023-12-31 $6,587,175 7,500
2023-12-31 $8,607,242 9,800
2023-09-30 $17,282,160 21,000
2023-09-30 $12,811,018 15,567
2023-09-30 $2,880,360 3,500
2023-06-30 $15,304,902 21,300
2023-06-30 $3,089,722 4,300
2023-06-30 $2,971,162 4,135
2023-03-31 $2,958,012 3,600
2023-03-31 $14,409,626 17,537
2023-03-31 $493,002 600
2022-12-31 $6,276,963 8,700
2022-12-31 $3,607,450 5,000
2022-12-31 $577,192 800
2022-09-30 $3,444,350 5,000
2022-09-30 $5,717,621 8,300
2022-06-30 $7,152,673 12,100
2022-06-30 $3,192,102 5,400
2022-03-31 $3,561,942 5,100
2022-03-31 $8,381,040 12,000
2021-12-31 $4,104,880 6,500
2021-12-31 $16,373,419 25,927

Report a Problem

Category
Description
Email (optional, for follow-up)